CN101490080A - 用于缓解和治疗缺血性病症的药物组合物及其输送方法 - Google Patents

用于缓解和治疗缺血性病症的药物组合物及其输送方法 Download PDF

Info

Publication number
CN101490080A
CN101490080A CNA2007800276518A CN200780027651A CN101490080A CN 101490080 A CN101490080 A CN 101490080A CN A2007800276518 A CNA2007800276518 A CN A2007800276518A CN 200780027651 A CN200780027651 A CN 200780027651A CN 101490080 A CN101490080 A CN 101490080A
Authority
CN
China
Prior art keywords
polypeptide
seq
fusion polypeptide
aminoacid sequence
ptd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800276518A
Other languages
English (en)
Chinese (zh)
Inventor
李尚揆
黄基哲
李承揆
张桹洙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ForHumanTech Co Ltd
Original Assignee
ForHumanTech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ForHumanTech Co Ltd filed Critical ForHumanTech Co Ltd
Publication of CN101490080A publication Critical patent/CN101490080A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2007800276518A 2006-07-24 2007-07-19 用于缓解和治疗缺血性病症的药物组合物及其输送方法 Pending CN101490080A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83258406P 2006-07-24 2006-07-24
US60/832,584 2006-07-24

Publications (1)

Publication Number Publication Date
CN101490080A true CN101490080A (zh) 2009-07-22

Family

ID=38997534

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800276518A Pending CN101490080A (zh) 2006-07-24 2007-07-19 用于缓解和治疗缺血性病症的药物组合物及其输送方法

Country Status (6)

Country Link
US (1) US7902154B2 (cg-RX-API-DMAC7.html)
EP (1) EP2044108A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009544688A (cg-RX-API-DMAC7.html)
KR (1) KR101574630B1 (cg-RX-API-DMAC7.html)
CN (1) CN101490080A (cg-RX-API-DMAC7.html)
WO (1) WO2008015580A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612384B (zh) * 2009-07-23 2012-06-20 中国人民解放军第二军医大学 多肽小分子mlif在制备防治心肌缺血药物中的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416383B2 (en) * 2007-04-27 2016-08-16 University Of North Carolina At Chapel Hill Method for enhancing catalytic activity of a lipase
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
KR101278221B1 (ko) * 2010-06-01 2013-06-24 연세대학교 산학협력단 Ρtd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー,リミティド 前立腺癌治療用組成物
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2015167067A1 (ko) * 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー,リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
ES2949697T3 (es) 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
KR20250057224A (ko) 2023-10-19 2025-04-29 단국대학교 천안캠퍼스 산학협력단 Pdrn을 이용한 유치줄기세포를 포함하는 세포치료제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920508A1 (en) 1996-08-23 1999-06-09 Chiron Corporation HUMAN POLYHOMEOTIC 1 ($i(hph1)) ACTS AS AN ONCOGENE
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
KR20030062788A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 mph1-btm 및 이것을포함하는 생명공학제품
KR20030062789A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 sim2-btm 및 이것을포함하는 생명공학제품
KR100591936B1 (ko) 2002-11-12 2006-06-22 포휴먼텍(주) 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7339042B2 (en) * 2003-06-09 2008-03-04 University Of Florida Research Foundation, Inc. Gene delivery to tumors
ATE478676T1 (de) 2005-11-04 2010-09-15 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
EP2057195A4 (en) 2006-08-29 2010-05-12 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE SUPPRESSION OF APOPTOSIS AND METHOD OF ADMINISTERING THE SAME

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612384B (zh) * 2009-07-23 2012-06-20 中国人民解放军第二军医大学 多肽小分子mlif在制备防治心肌缺血药物中的应用

Also Published As

Publication number Publication date
US7902154B2 (en) 2011-03-08
EP2044108A2 (en) 2009-04-08
WO2008015580A3 (en) 2008-06-26
JP2009544688A (ja) 2009-12-17
WO2008015580A2 (en) 2008-02-07
US20090087422A1 (en) 2009-04-02
KR101574630B1 (ko) 2015-12-07
KR20090033878A (ko) 2009-04-06
EP2044108A4 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
US7902154B2 (en) Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same
KR20090045940A (ko) 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법
CN100509846C (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
KR100966232B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
US6924266B2 (en) NTP-peptides and method for removal of tumors
CN101389760A (zh) 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽
EP1368054B1 (en) Using neural thread proteins to treat tumors
CN114099636A (zh) 使用来源于神经丝蛋白的肽治疗需要破坏或移除细胞的病症的方法
US8409826B2 (en) TAT-utrophin as a protein therapy for dystrophinopathies
KR101695980B1 (ko) 세포 투과성 펩타이드
CN100537602C (zh) Ec sod和细胞转导性ec sod及它们的用途
US9567369B2 (en) Method of treating metastatic cancer
US10479816B2 (en) Decoy peptides inhibiting protein phosphatase 1-medicated dephosphorylation of phospholamban
WO2008051048A2 (en) Method and materials for inhibiting a nuclear export of gsk3
US7601366B2 (en) Promotion of peroxisomal catalase function in cells
WO2024021383A1 (zh) gp96及其在治疗肌萎缩侧索硬化的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090722